Lithium augmentation of venlafaxine in adolescent major depression

Australian and New Zealand Journal of Psychiatry

Volumn 32, Issue 3, 1998, Pages 457-459

  Walter, Garry ^a,b   Lyndon, Bill ^a,c   Kubb, Rosie ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Rivendell Child & Adolescent Unit   (Australia)

^c Northside Clinic   (Australia)

^d CENTRAL SYDNEY AREA HEALTH SERVICE   (Australia)

Author keywords

Adolescent; Lithium augmentation; Major depression; Venlafaxine

Indexed keywords

LITHIUM; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADOLESCENT; ARTICLE; CASE REPORT; DEPRESSION; FEMALE; HUMAN; MALE; MOOD; PSYCHOTHERAPY;

EID: 0031780964     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.3109/00048679809065541     Document Type: Article

References (13)

1. National Health and Medical Research Council. Depression in young people: clinical practice guidelines. Canberra: Australian Government Publishing Service, 1997.
2. Burke KC, Burke JD, Regier DA, Rae DS. Age of onset of selected mental disorders in five community populations. Archives of General Psychiatry 1990; 47:511-518.
3. Kandel DB, Davies M. Adult sequelae of adolescent depressive symptoms. Archives of General Psychiatry 1986; 43:255-262.
4. Hazell P, O'Connell D, Heathcote D, Robertson J, Henry D. A meta-analysis of the efficacy of the tricyclics in the treatment of child and adolescent depression. British Medical Journal 1995; 310:897-901.
5. Ryan ND, Puig-Antich J, Rabinovich H et al. MAOIs in adolescent major depression unresponsive to tricyclic antidepressants. Journal of the American Academy of Child and Adolescent Psychiatry 1988; 27:755-758.
6. Sherman C. Prozac for kids: landmark study affirms drug's use. Clinical Psychiatry News 1995; 23.1.
7. Emslie GJ, Rush AL, Weinberg WA et al. A double-blind, randomised, placebo-controlled trial of fluoxetine in children and adolescents. Archives of General Psychiatry 1997; 54:1031-1037.
8. Simeon JG, Dinicola VF, Ferguson HB, Copping W. Adolescent depression: a placebo controlled fluoxetine treatment study and follow-up. Progress in Neuropsychopharmacological Biological Psychiatry 1990; 14:791-795.
9. Mandoki MW, Tapia MR, Tapia MA, Sumner GS, Parker JL. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacology Bulletin 1997; 33:149-154.
10. Ryan ND, Meyer V, Dachille S, Mazzie D, Puig-Antich J. Lithium antidepressant augmentation in TCA-refractory depression in adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 1988; 27:371-376.
11. Strober M, Freeman R, Rigali J, Schmidt S, Diamond R. The pharmacotherapy of depressive illness in adolescence: effects of lithium augmentation in nonresponders to imipramine. Journal of the American Academy of Child and Adolescent Psychiatry 1992; 31:16-20.
12. Schweitzer I, Tuckwell V, Johnson G. A review of the use of augmentation therapy for the treatment of resistant depression: implications for the clinician. Australian and New Zealand Journal of Psychiatry 1997; 31:340-352.
13. Troy SM. Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium. Journal of Clinical Pharmacology 1996; 36:175-181.